Glypican-3–specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma SA Batra, P Rathi, L Guo, AN Courtney, J Fleurence, J Balzeau, RS Shaik, ... Cancer immunology research 8 (3), 309-320, 2020 | 160 | 2020 |
Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside J Fleurence, D Cochonneau, S Fougeray, L Oliver, F Geraldo, M Terme, ... Oncotarget 7 (27), 41172, 2016 | 63 | 2016 |
Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy J Fleurence, S Fougeray, M Bahri, D Cochonneau, B Clémenceau, ... Journal of immunology research 2017, 2017 | 34 | 2017 |
Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development A Desselle, T Chaumette, MH Gaugler, D Cochonneau, J Fleurence, ... PloS one 7 (11), e45423, 2012 | 28 | 2012 |
Impairing temozolomide resistance driven by glioma stem‐like cells with adjuvant immunotherapy targeting O‐acetyl GD2 ganglioside J Fleurence, M Bahri, S Fougeray, S Faraj, S Vermeulen, E Pinault, ... International Journal of Cancer 146 (2), 424-438, 2020 | 26 | 2020 |
Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside S Faraj, M Bahri, S Fougeray, A El Roz, J Fleurence, J Véziers, MD Leclair, ... Oncoimmunology 7 (1), e1373232, 2018 | 17 | 2018 |
O-acetylated gangliosides: Structure, biosynthesis, immunogenicity, functions and their potential for cancer immunotherapy S Fougeray, J Fleurence, S Faraj, M Bahri, D Cochonneau, M Terme, ... Journal of Cancer Research and Therapeutics 4 (3), 21-30, 2016 | 6 | 2016 |
Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting S Birklé, A Desselle, T Chaumette, MH Gaugler, D Cochonneau, ... Oncoimmunology 2 (4), e23700, 2013 | 6 | 2013 |
Potentiation of anticancer antibody efficacy by antineoplastic drugs: detection of antibody-drug synergism using the combination index equation M Bahri, J Fleurence, S Faraj, MBM Daho, S Fougeray, S Birklé JoVE (Journal of Visualized Experiments), e58291, 2019 | 5 | 2019 |
A phase 1 clinical trial using armored GPC3-car T cells for children with relapsed/refractory liver tumors DHM Steffin, N Ghatwai, S Batra, JJ Fleurence, P Rathi, AN Courtney, ... MOLECULAR THERAPY 28 (4), 212-213, 2020 | 1 | 2020 |
Use of antibody against o-acetylated gd2 ganglioside to improve the therapeutic potential of drugs S Birkle, J Fleurence, S Faraj, JM Le Doussal, D Cochonneau, M Terme, ... US Patent App. 18/321,094, 2023 | | 2023 |
Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs S Birkle, J Fleurence, S Faraj, JM Le Doussal, D Cochonneau, M Terme, ... US Patent 11,697,689, 2023 | | 2023 |
Glypican-3-Specific CAR NKT Cells Armored with IL-15 Mediate Potent Anti-Tumor Response Against Hepatocellular Carcinoma R Shaik, P Rathi, N Schneller, T Nguyen, L Guo, A Courtney, J Fleurence, ... MOLECULAR THERAPY 28 (4), 34-35, 2020 | | 2020 |
UTILISATION D'UN ANTICORPS CONTRE LE GANGLIOSIDE GD2 O-ACÉTYLÉ DANS LE BUT D'AMÉLIORER LE POTENTIEL THÉRAPEUTIQUE DE MÉDICAMENTS S Birklé, J Fleurence, S Faraj, JM Le Doussal, D Cochonneau, M Terme, ... | | 2019 |
Ciblage du GD2-O-acétylé par un anticorps monoclonal dans le glioblastome multiforme J Fleurence Nantes, 2017 | | 2017 |
Journal of Cancer Research & Therapy Volume 4, Issue 3, August 2016, Pages 21–30 Review Open Access S Fougeray, J Fleurence, S Faraj, M Bahri, D Cochonneau, M Terme, ... | | |